University of Texas, Arlington NURS 5334/NURS5334: Quiz
2 40 Questions and Answers (explained) | 100% correct
2025/26.
Section 1: Pharmacokinetics & Pharmacodynamics
(Questions 1–12)
1. A patient with end-stage renal disease (eGFR <15 mL/min) is prescribed a
medication that is 70% renally excreted. The nurse practitioner should anticipate:
A. Increasing the dose by 50%
B. Decreasing the dosing frequency
C. Changing to a prodrug
D. Adding a diuretic to enhance excretion
Answer: B — Reduced renal clearance leads to drug accumulation. Decreasing
frequency maintains therapeutic levels without toxicity .
2. Which cytochrome P450 enzyme is most commonly involved in clinically
significant drug-drug interactions?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
Answer: C — CYP3A4 metabolizes approximately 50% of marketed drugs and is highly
susceptible to inhibition and induction .
, 3. A drug with high first-pass effect is given orally. The NP understands that:
A. The drug will have increased bioavailability
B. The drug must be given via a non-oral route to avoid extensive hepatic metabolism
C. Gastric pH will alter absorption significantly
D. Protein binding will be decreased
Answer: B — High first-pass effect means the liver metabolizes much of the drug
before it reaches systemic circulation .
4. A patient takes warfarin. Starting rifampin (a potent CYP inducer) will likely:
A. Increase INR and bleeding risk
B. Decrease INR and reduce anticoagulant effect
C. Have no effect on INR
D. Cause warfarin toxicity
Answer: B — Rifampin induces CYP enzymes that metabolize warfarin, reducing its
anticoagulant effect .
5. What is the study of drug movement throughout the body called?
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics
Answer: B — Pharmacokinetics encompasses absorption, distribution, metabolism, and
excretion (ADME) .
6. A patient with liver cirrhosis has reduced synthesis of albumin. The NP should
anticipate that a highly protein-bound drug will have:
2 40 Questions and Answers (explained) | 100% correct
2025/26.
Section 1: Pharmacokinetics & Pharmacodynamics
(Questions 1–12)
1. A patient with end-stage renal disease (eGFR <15 mL/min) is prescribed a
medication that is 70% renally excreted. The nurse practitioner should anticipate:
A. Increasing the dose by 50%
B. Decreasing the dosing frequency
C. Changing to a prodrug
D. Adding a diuretic to enhance excretion
Answer: B — Reduced renal clearance leads to drug accumulation. Decreasing
frequency maintains therapeutic levels without toxicity .
2. Which cytochrome P450 enzyme is most commonly involved in clinically
significant drug-drug interactions?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
Answer: C — CYP3A4 metabolizes approximately 50% of marketed drugs and is highly
susceptible to inhibition and induction .
, 3. A drug with high first-pass effect is given orally. The NP understands that:
A. The drug will have increased bioavailability
B. The drug must be given via a non-oral route to avoid extensive hepatic metabolism
C. Gastric pH will alter absorption significantly
D. Protein binding will be decreased
Answer: B — High first-pass effect means the liver metabolizes much of the drug
before it reaches systemic circulation .
4. A patient takes warfarin. Starting rifampin (a potent CYP inducer) will likely:
A. Increase INR and bleeding risk
B. Decrease INR and reduce anticoagulant effect
C. Have no effect on INR
D. Cause warfarin toxicity
Answer: B — Rifampin induces CYP enzymes that metabolize warfarin, reducing its
anticoagulant effect .
5. What is the study of drug movement throughout the body called?
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics
Answer: B — Pharmacokinetics encompasses absorption, distribution, metabolism, and
excretion (ADME) .
6. A patient with liver cirrhosis has reduced synthesis of albumin. The NP should
anticipate that a highly protein-bound drug will have:
